Table S1 Use the Miller-Payne system to measure the tumor burden after alternative chemotherapy based on vinorelbine

	Whole cohort	Luminal	HER2	TNBC
Total	65	18	15	32
G1	18	4	7	7
G2	11	2	2	7
G3	21	8	4	9
G4	5	3	2	0
G5	10	1	0	9

HER2, human epidermal growth factor receptor 2.

Table S2 Use the residual cancer burden to measure tumor burden after alternative chemotherapy based on vinorelbine

	Whole cohort	Luminal	HER2	TNBC
Total	65	18	15	32
0/RCB-0	9	1	0	8
RCB-I	4	1	2	1
RCB-II	28	9	5	14
RCB-III	24	7	8	9

HER2, human epidermal growth factor receptor 2.